PROFILBARU.COM

Bimatoprost
IUPAC ime
	7-[3,5-dihidroksi-2- (3-hidroksi-5-fenil-pent-1-enil)- ciklopentil]-N-etil-hept-5-enamid
Klinički podaci
Prodajno ime	Lumigan
Drugs.com	Monografija
MedlinePlus	a602030
Podaci o licenci	US DailyMed: 46098;
Kategorija trudnoće	US: C (Mogući rizik) ; ;
Način primene	Topikalni (kapi za oči)
Pravni status
Pravni status	US: ℞-only ;
Identifikatori
CAS broj	155206-00-1
ATC kod	S01EE03 (WHO)
PubChem	CID 5311027
IUPHAR/BPS	1958
DrugBank	DB00905
ChemSpider	4470565
UNII	QXS94885MZ
ChEBI	CHEBI:51230
ChEMBL	CHEMBL1200963
Hemijski podaci
Formula	C25H37NO4
Molarna masa	415,566 g/mol
	SMILES O=C(NCC)CCC/C=C\C[C@H]2[C@@H](O)C[C@@H](O)[C@@H]2/C=C/[C@@H](O)CCc1ccccc1; ;
	InChI InChI=1S/C25H37NO4/c1-2-26-25(30)13-9-4-3-8-12-21-22(24(29)18-23(21)28)17-16-20(27)15-14-19-10-6-5-7-11-19/h3,5-8,10-11,16-17,20-24,27-29H,2,4,9,12-15,18H2,1H3,(H,26,30)/b8-3-,17-16+/t20-,21+,22+,23-,24+/m0/s1 ; Key:AQOKCDNYWBIDND-FTOWTWDKSA-N ;

Bimatoprost (Lumigan) je analog prostaglandina. On je prolek koji se koristi topikalni (u obliku kapi za oči) za kontrolu progresa glaukoma i okularne hipertenzije. On redukuje intraokularni pristisak (IOP) putem povećanja odliva fluida iz očiju.^[1] Poznato je da se koristi za produžavanje trepavica.^[2] FDA je odobrila ovaj način primene decembra 2008. Kozmetička formulacija bimatoprosta je u prodaji pod imenom Latis.^[3] Tokom perioda od 2008 - 2011, utvrđeno je da bimatoprost ima sposobnost redukovanja masnog tkiva.^[4]^[5]^[6]

Reference

^ „Bimatoprost Ophthalmic”. MedlinePlus. 1. 1. 2003. Архивирано из оригинала 05. 10. 2007. г. Приступљено 19. 11. 2007.
^ Rundle, Rhonda L. (19. 11. 2007). „Drug That Lengthens Eyelashes Sets Off Flutter”. The Wall Street Journal. Приступљено 19. 11. 2007.
^ „Allergan gets FDA approval for eyelash treatment”. BusinessWeek. Associated Press. 26. 12. 2008. Приступљено 26. 12. 2008.
^ Park J, Cho HK, Moon JI (2011). „Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost.”. Japanese Ophthalmological Society. 55 (1): 22—27. PMID 21331688. doi:10.1007/s10384-010-0904-z.
^ Jayaprakasam A, Ghazi-Nouri S (2010). „Periorbital fat atrophy - an unfamiliar side effect of prostaglandin analogues.”. Orbit. 29 (6): 357—359. PMID 21158579. doi:10.3109/01676830.2010.527028.
^ Filippopoulos T, Paula JS, Torun N, Hatton MP, Pasquale LR, Grosskreutz CL (2008). „Periorbital changes associated with topical bimatoprost.”. Ophthalmology Plastic and Reconstructive Surgery. 24 (4): 302—307. PMID 18645437. doi:10.1097/IOP.0b013e31817d81df.

Literatura

Chen M, Cheng C, Chen Y, Chou C, Hsu W (2006). „Effects of bimatoprost 0.03% on ocular hemodynamics in normal tension glaucoma.”. J Ocul Pharmacol Ther. 22 (3): 188—93. PMID 16808680. doi:10.1089/jop.2006.22.188.
Kruse P, Rieck P, Sherif Z, Liekfeld A (2006). „Cystoid macular edema in a pseudophakic patient after several glaucoma procedures. Is local therapy with bimatoprost the reason?”. Klinische Monatsblätter für Augenheilkunde. 223 (6): 534—7. PMID 16804825. doi:10.1055/s-2005-858992.
Steinhäuser S (2006). „Decreased high-density lipoprotein serum levels associated with topical bimatoprost therapy.”. Optometry. 77 (4): 177—9. PMID 16567279. doi:10.1016/j.optm.2006.02.001.
Park J, Cho HK, Moon JI (2011). „Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost.”. Japanese Ophthalmological Society. 55 (1): 22—27. PMID 21331688. doi:10.1007/s10384-010-0904-z.
Jayaprakasam A, Ghazi-Nouri S (2010). „Periorbital fat atrophy - an unfamiliar side effect of prostaglandin analogues.”. Orbit. 29 (6): 357—359. PMID 21158579. doi:10.3109/01676830.2010.527028.
Filippopoulos T, Paula JS, Torun N, Hatton MP, Pasquale LR, Grosskreutz CL (2008). „Periorbital changes associated with topical bimatoprost.”. Ophthalmology Plastic and Reconstructive Surgery. 24 (4): 302—307. PMID 18645437. doi:10.1097/IOP.0b013e31817d81df.

Spoljašnje veze

Medical News Today: FDA Seizes $2 Million Of Cosmetic Eye Product Which Contains Drug Ingredient And Makes Unapproved Drug Claims. Christian Nordqvist. 18 November 2007
Wired Science: FDA Seizes Cosmetic That Can Blind. Brandon Keim. November 19, 2007

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[MedlinePlus-1] „Bimatoprost Ophthalmic”. MedlinePlus. 1. 1. 2003. Архивирано из оригинала 05. 10. 2007. г. Приступљено 19. 11. 2007.

[WSJ-19-11-2007-2] Rundle, Rhonda L. (19. 11. 2007). „Drug That Lengthens Eyelashes Sets Off Flutter”. The Wall Street Journal. Приступљено 19. 11. 2007.

[3] „Allergan gets FDA approval for eyelash treatment”. BusinessWeek. Associated Press. 26. 12. 2008. Приступљено 26. 12. 2008.

[JapaneseOphSociety-4] Park J, Cho HK, Moon JI (2011). „Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost.”. Japanese Ophthalmological Society. 55 (1): 22—27. PMID 21331688. doi:10.1007/s10384-010-0904-z.

[Orbit-5] Jayaprakasam A, Ghazi-Nouri S (2010). „Periorbital fat atrophy - an unfamiliar side effect of prostaglandin analogues.”. Orbit. 29 (6): 357—359. PMID 21158579. doi:10.3109/01676830.2010.527028.

[OphthPlasReconSurg-6] Filippopoulos T, Paula JS, Torun N, Hatton MP, Pasquale LR, Grosskreutz CL (2008). „Periorbital changes associated with topical bimatoprost.”. Ophthalmology Plastic and Reconstructive Surgery. 24 (4): 302—307. PMID 18645437. doi:10.1097/IOP.0b013e31817d81df.

[1]

[2]

[3]

[4]

[5]

[6]